Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $184 to $194.
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $184 to $194.